Fig. 4From: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysisForest plot comparing across interventions the number of women with ≥ 1 g/dL increase in hemoglobin levels after treatmentBack to article page